PaulJ.PockrosMD

PubMed

• Lessons From COBALT: Will the Bell Also Toll for Thee?
  John Moore Vierling, Paul J Pockros
  The American Journal of Gastroenterology. 2024-10-02
• Latent Autoimmune Diabetes in Adults (LADA) Occurring in a Patient with Primary Biliary Cholangitis.
  Byung K Lee, Kevin Pak, Paul J Pockros
  The American Journal of Medicine. 2024-09-18
• 8 citations
  Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study.
  Christopher L Bowlus, Bertus Eksteen, Angela C Cheung, Douglas Thorburn, Cynthia A Moylan
  Hepatology Communications. 2023-06-01

Journal Articles

• A phase 2, randomized, double-blind, placebo-controlled study of maralixibat chloride in the treatment of primary biliary cholangitis associated with itching  
  Mayo MJ, Pockros PJ, Jones D, et al, Hepatology Communications, 1/1/2019
• Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease  
  Bernstein DE, Tran A, Martin P, Kowdley KV, Bourliere M, Sulkowski MS, Pockros PJ, et al, Kidney Int Rep, 1/1/2019
• Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients with Hepatitis C Virus Genotype 1 or 4 Infection and Severe Renal Impairment or End-Stage Renal Di...  
  Lawitz E, Gane E, Cohen E, Vierling J, Agarwal K, Hassanein T, Mantry PS, Pockros PJ, et al, Kidney Int Rep, 1/1/2019
• Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients with Genotype 1 Hepatitis C Virus Infection and Cir...  
  Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, et al, Clin Gastroenterol Hepatol, 1/3/2018
• Efficacy of Elbasvir and Grazoprevir with or without Ribavirin in Treatment-Naive and Experienced Patients with Hepatitis C Virus Genotype 4 Infection: A Pooled Analysis  
  Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, et al, Liver Int, 1/1/2018
• Chronic hepatitis B combination therapy: success as proof-of-concept for future hepatitis B eradication?  
  Khu QM and Pockros PJ, Aliment Pharmacol Ther, 1/1/2018
• Management of Patients Who Have Achieved Sustained Virologic Response for Hepatitis C Virus Infection  
  Pockros PJ, Gastroenterol Hepatol, 1/1/2018
• Transient Elastography Overestimates Fibrosis Regression from Sustained Virologic Response to Direct-Acting Antivirals for Hepatitis C  
  Pan JJ, Bao F, Du E, Skillin C, Frenette C, Waalen J, Alaparthi L, Goodman ZD, Pockros PJ, Hepatology Communications, 1/1/2018
• Novel emerging treatments for hepatitis C infection A fast- moving pipeline  
  Kardashian A, Pockros PJ, Therap Adv Gastroenterol, 1/1/2017
• All-oral Direct-acting Antiviral Therapy in HCV-advanced liver disease is effective in real-world practice: Observations through HCV TARGET database  
  Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G, Everson GT, Kwo PY, Brown RS Jr, Sulkowski MS, Akuschevich L, Lok AS, Pockros PJ, et al, Aliment Pharmacol Ther, 1/1/2017
• Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection  
  Pockros PJ, Gastroenterol Hepatol (NY), 1/1/2017
• Daclatasvir in Hepatitis C Virus Genotype 1 and 3 Treatment  
  Kardashian A, Pockros PJ, Future Medicine, 1/1/2017
• Pulmonary Complications of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma  
  Quan M Nhu, Paul J Pockros, World Journal of Gastroenterology
• HCV Council - Critical Appraisal of Data: Recommendations for Clinical Practice in a Rapidly Evolving Therapeutic Landscape  
  Reau N, Fried MW, Nelson DR, Brown RS Jr, Everson GT, Gordon SC, Jacobson IM, Lim JK, Pockros PJ, et al, Liver Int, 1/1/2016
• Faldaprevir, deleobuvir, and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 Phase 2b study  
  Zeuzem S, Mantry P,Soriano V, Buynak RJ, Dufour JF, Pockros PJ, et al, Eur J Gastroenterol Hepatol, 1/1/2016
• Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients with Hepatitis C Virus Infection and Factors Associated of Sustained Virologic Response  
  Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, et al, Gastroenterology, 1/1/2016
• Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection  
  Sulkowski MS, Vargas HE, Di Bisceglie AM, et al.; HCV-TARGET Study Group (Pockros PJ), Gastroenterology, 1/1/2016
• An Unexpected Pulmonary Complication Following Transcatheter Arterial Chemoembolization of a Small Hepatocellular Carcinoma  
  Nhu QM, Knowles H, Pockros PJ, Frenette CT, J Clin Gastroenterol, 1/1/2016
• MicroRNA changes in liver tissue associated with fibrosis progression in patients with Hepatitis-C  
  Keuren-Jensen KV, Malenica I, Courtright A, Ghaffari L, Starr A, Metpally R, Beecroft T , Carlson E, Pockros PJ, Rakela J, Liver Int, 1/1/2016
• Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-a and -b, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening  
  Ratziu V, Harrison S, Francque S, GOLDEN-505 Investigator Study Group (Pockros PJ), Gastroenterology, 1/1/2016
• HCV Genotype 1 Treatment for Patients with Severe Renal Impairment or End-Stage Renal Disease  
  Pockros PJ, Reddy KR, Mantry PS, et al, Gastroenterology, 1/1/2016
• An International Study of Obeticholic Acid in Primary Biliary Cirrhosis: the First PBC Therapy Targeting the Farnesoid X Receptor  
  Nevens F, Andreone P, Mazzella G, Strasser S, Bowlus C, Invernizzi P, Drenth JPH, Pockros PJ, et al, N Engl J Med, 1/1/2016
• Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma  
  Nhu QM, Knowles H, Pockros PJ, Frenette CT, World J Respirol, 1/1/2016
• A Genome Sequencing Program for Novel Undiagnosed Diseases  
  Bloss CS, Van Zeeland A, Darst BF, Boeldt DL, Erikson GA, Bethel K, Friedman JR, Hwynn N, Patay B, Pockros PJ, et al, Genet Med, 1/1/2015
• Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study  
  Gane EJ, Pockros PJ, Zeuzem S, et al, Liver Int, 1/1/2015
• Join now to see all

Books/Book Chapters

• Controversies in Hepatology: The Experts Analyze Both Sides 
  Chapter: Should the decompensated Hepatitis C Cirrhotic Be Treated with Antiviral Therapy. 
  Page 43 - 49Afshar P, Weissman J, Pockros PJEditors: D. Jensen.Slack, Inc.2011
• Conn's Current Therapy 2000 
  Chapter: Cirrhosis. 
  Page 465 - 471Pockros PEditors: Rakel RE.W.B. Saunders Co., Philadelphia, PA2000
• Schiff's Diseases of the Liver 
  Chapter: Postoperative jaundice. 
  Page 599 - 605Nyberg LM, Pockros PJEditors: Schiff ER, Sorrell ME, Maddrey WC.Lippincott-Raven Publishers, Philadelphia, PAEdition 8th,1999
• Bockus Gastroenterology 
  Chapter: Microvesicular fat diseases of the liver. 
  Page 2254 - 2275Pockros PJ, Esrason KTEditors: Haubrich WS, Schaffner F.W.B. Saunders Co., Philadelphia, PAEdition 5th,1995
• Join now to see all

Abstracts/Posters

• Comparative Diagnostic Performance of the PROMETHEUS (R) FIBROSpect (R) NASH Serum Test with Enhanced Liver Fibrosis (ELF TM) Test for the Identification of Advanced L...
  Jain A, Pockros P, Thomas S, et al, NASH-TAG, Park City, UT, 1/3/2019
• Three years of Obeticholic Acid (OCA) Therapy Results in Histological Improvements in Patients with Primary Biliary Cholangitis: Further Analysis of the POISE Biopsy S...
  Bowlus CL, Pockros P, Kremer AE, et al, GASL 2019 - 35th Annual Conference of the German Association for the Study of the Liver, Berlin, Germany, 1/1/2019
• Three years of Obeticholic Acid (OCA) Therapy Results in Histological Improvements in Patients with Primary Biliary Cholangitis: Further Analysis of the POISE Biopsy S...
  Bowlus CL, Pockros P, Kremer AE, et al, Canadian Liver Meeting, Montreal, Canada, 1/1/2019
• Safety and Efficacy of Glecaprevir/Pibrentasvir in Adults with Chronic Hepatitis C Virus Infection Genotype 1 - 6 as a Function of Chronic Kidney Disease Stage.
  Pol S, Pockros P, Pugatch D, et al, Singapore Hepatology Conference, Singapore, 1/8/2018
• Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC).
  Bowlus CL, Pockros P, Kremer AE, et al, J Hepatology; UEG Week, Vienna, Austria, 1/1/2018
• Treatment with obeticholic acid in patients with NASH does not show increased markers of liver toxicity based on evaluation of drug-induced serious hepatotoxicity.
  Sanyal A, Shah A, Pockros P, et al, J Hepatology, 1/1/2018
• Durable Response in the Markers of Cholestasis through 24 Months of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis.
  Trauner M, Nevens F, Andreone P, Mazzella G, Strasse S, Invernizzi CP, Drenth JPH, Pockros P, et al, 25th United European Gastroenterology Week Gastroenterology Conference, Barcelona, Spain, 1/28/2017
• Intramural Expression of Tregs Predicts Prognosis in Patients with Hepatocellular Carcinoma.
  Baquerizo A, Krol V, Frenette C, Skillin C, Mhoyan A, Madani B, Fisher J, Schaffer, Pockros P, Marsh C, AASLD The Liver Meeting, Washington, DC, 1/20/2017
• Hepatitis C: Therapeutics: Preclinical and Early Cliniocal Devlopment; Therapeutics: New Agents (not approved, phase 2-3).
  Feld JJ, Firpi RJ, Gordon F, Gordon SC, Nelson DR, Pockros PJ, AASLD The Liver Meeting, Washington, DC, 1/20/2017
• Protein Expression in Hepatocellular Carcinoma Biopsies.
  Baquerizo A, Simonian M, Schaffer R, Frenette C, Nelson M, Fisher J, Madani B, Pockros P, Marsh C, American Transplant Congress, 1/1/2017
• Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1-6 and chronic kidney disease: an integrated analysis.
  Pol S, Pockros P, Pugatch D, et al, Gastroenterology, 1/1/2017
• Serum fibroblast growth factor 19 (FGF19), 7?-Hydroxy-4-Cholesten-3-one (C4), and bile acids and their?associations with clinical characteristics in primary sclerosing...
  Levy C, Shiffman M, Caldwell S, Luketic V, Invernizzi P, Minuk G, Pockros P, et al, Journal of Hepatology, 1/1/2017
• Degree of Liver Fibrosis Regression Predicted by Transient Elastography after Cure of Chronic Hepatitis C with? Direct Acting Antivirals is Overestimated but Confirmed...
  Pockros P, Crissien-Martinez AM, Frenette C, et al, Journal of Hepatology, 1/1/2017
• Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1-6 and chronic kidney disease: an integrated analysis.
  Pol S, Pockros P, Pugatch D, et al, Journal of Hepatology, 1/1/2017
• When are we done? How long do we follow patients with advanced fibrosis and cirrhosis after SVR?
  Pockros P, Reviews in Antiviral Therapy& Infectious Diseases, 1/1/2017
• Dasabuvir with Low-Dose Ribavirin QD in Patients with Genotype 1a Chronic Hepatitis C Infection Without Cirrhosis.
  Poordad F, Sedghl S, Pockros PJ, et al, EASL Special Conference, Paris, France, 1/23/2016
• RCT of IFN-intolerant/ineligible GT1 patients (TN or TE) including LDV/SOF failures with NS5A RAVs using SMV+SOF +/- RBV for 12/24 weeks.
  Skillin C, Box T, Agarwal R, Pockros PJ, 8th International Conference on Clinical Gastroenterology & Hepatology, Toronto, Canada, 1/3/2016
• Predictors of Improvement in Glomerular Filtration Rate Among Patients Treated with Ombitasvir/Paritaprevir/r and Dasabuvir with or without RBV.
  Bernstein D, Tran A, Martin P, Kowdley K, Bourli�re M, Sulkowski MS, Pockros P, et al, 79th Annual Meeting of the Societe Fran�aise D'Hepatologie (AFEF), Bordeaux, France, 1/1/2016
• Safety And Effectiveness Of 12 And 24-Week Regimens Of Ledipasvir/SfofosbuvirR (LDV/SOF) In Treatment Experienced Genotype 1 Cirrhosis: Interim Analysis HCV-Target, A ...
  Shiffman ML, Lim JK, Lok AS, Zeuzem S, Terrault N, Park J , Landis CS ,Hassan MA,Gallant JE, Kuo AA, Pockros PJ , et al, AASLD-EASL Single Topic Conference, Paris, France, 1/1/2016
• Ledipasvir/Sofosbuvir Regimens for the Retreatment of Patients Who Failed Sofosbuvir-Based Regimens.
  Lawitz E, Pockros P, Yang JC, et al, APASL, Tokyo, Japan, 1/1/2016
• Analysis of the Efficacy of OCA in Primary Biliary Cholangitis by Baseline Biochemistry Across Three Randomized, Double-Blind, Placebo-Controlled Clinical Trials.
  Pockros PJ, Lutz K, Pencek R, Marmon T, MacConell L, Picaro L, Adorini L, Shapiro D, American J Gastro, 1/1/2016
• Final SVR24 Data From The Phase 3 C-EDGE Treatment-Naive Study Of Elbasvir (EBR)/Grazoprevir (GZR) In Patients With Chronic HCV Genotype 1, 4 OR 6 Infection.
  Zeuzem S, Ghalib R, Reddy KR, Pockros P, et al, Hepatology, 1/1/2016
• Al-Oral Treatment with Daclatasvir Plus Sofosbuvir �Ribavirin in HCV Genotype 3-Infected Patients With Advanced Fibrosis Or Cirrhosis: An Analysis Of ALLY-3 And ALLY-3+.
  Kowdley K, Angus P, Bernstein D, Bronowicki J.-P, Leroy V, Pockros P, R, et al, J Hepatology, 1/1/2016
• CLARITY: A Phase 2, Randomized, Double-Blind, Placebo Controlled Study of Lopixibat Chloride (Formerly LUM001), A Novel Apical Sodium-Dependent Bile Acid Transporter I...
  Mayo MJ, Pockros P, Jones D, et al, J Hepatology, 1/1/2016
• RUBY-I: Ombitasvir/Parataprevir/Ritonavir + Dasabuvir +/- Ribavirina En Pacientas No Cirroticos VHC Genotipo 1 Con Enfermadad Renal Avanzada. Infecciones virales: estu...
  Pockros P, Reddy R, Mantry PS, et al, SADI, 1/1/2016
• Join now to see all

Lectures

• What�s Next for PBC? 
  University of Maryland School of Medicine, Baltimore, MD - 1/1/2019
• Update: Hepatitis C Abstracts from AASLD. 
  Multiple Locations, 2014, 2015, 2016, 2017, 2018 - 1/1/2018
• Updates on HBV and HCV (post-EASL Update). 
  San Diego, CA - 1/1/2018
• Optimizing HCV Management within a System of Care: A Focus on Utilizing the PCMH Model to Improve Screening, Treatment, and Outcomes. 
  San Diego, CA - 1/1/2018
• Roadmap to cure for chronic hepatitis B and C infections worldwide. 
  The Scripps Research Institute Graduate Studies, La Jolla, CA - 1/1/2018
• The ABCs of PBC: An Overview of Primary Biliary Cirrhosis, Also Known as Primary Biliary Cholangitis. 
  University of New Mexico, Albuquerque, NM - 1/1/2018
• HCV: Are we at The End? 
  University of Utah, Salt Lake, UT - 1/1/2018
• Global Epidemic of Viral Hepatitis and the WHO Plan for Eradication. 
  Doha, Qatar - 1/1/2017
• Update in Hepatology 
  Doha, Qatar - 1/1/2017
• When are we done? How long do we follow patients with advanced fibrosis and cirrhosis after SVR? 
  Kona, HI - 1/1/2017
• Update on HCV Treatment. 
  Las Vegas, NV - 1/1/2017
• Real World Application for Current Hep C Therapies and What To Do With Resistance. 
  San Antonio, TX - 1/1/2017
• Update in Gastroenterology and Hepatology: Evidence Published in 2016. 
  San Diego, CA - 1/1/2017
• New Hepatitis C Therapies in 2017. 
  San Diego, CA - 1/1/2017
• HCV Treatment: Focus on Traditionally Difficult-To-Treat Patients. 
  Tokyo, Japan - 1/1/2017
• Hepatitis C: Update in Management. 
  Tyson�s Corner, VA - 1/1/2017
• Diagnosis and Treatment of HCV in ESRD Patients. 
  University of Pennsylvania, Philadelphia, PA - 1/1/2017
• Chronic Hepatitis C: Who to Treat and When. 
  University of Utah, Salt Lake, UT - 1/1/2017
• HCV Patient PopulationsWith Challenging Treatment Decisions: Genotype 3, Treatment Failures, and Decompensated Cirrhosis Patients Eligible for Liver Transplantation. 
  Washington, DC - 1/1/2017
• Current Therapies for Chronic Hepatitis C. 
  Dallas, TX - 1/1/2016
• Clinical Implications of Resistance to Direct-Acting Antivirals 
  Houston, TX - 1/1/2016
• Up-to-Date Therapeutic Options for Treatment of HCV Genotypes 1-6 Infections 
  Houston, TX - 1/1/2016
• Analysis of the Efficacy of OCA in Primary Biliary Cholangitis by Baseline Biochemistry Across Three Randomized, Double-Blind, Placebo-Controlled Clinical Trials. 
  Las Vegas, NV - 1/1/2016
• Hepatitis B Update 
  New Haven, CT - 1/1/2016
• Hepatitis C: Future Therapies. 
  New Haven, CT - 1/1/2016
• Join now to see all

Other

• Direct-acting antivirals for the treatment of hepatitis C virus infection. 
  Pockros PJ, UpToDate
  1/1/2016
• Overview of the management of chronic hepatitis C virus infection. 
  Chopra S, Pockros PJ, UpToDate
  1/31/2015
• HCV Infection: Update on Diagnosis. 
  Pockros PJ, Audio-Digest Gastroenterology
  1/1/2015
• Directly acting antivirals for the treatment of hepatitis C virus infection. 
  Pockros PJ, UpToDate
  1/28/2014
• Join now to see all